HK1218760A1 - 包含重组人凝血因子xa蛋白的异质性群体的组合物 - Google Patents

包含重组人凝血因子xa蛋白的异质性群体的组合物 Download PDF

Info

Publication number
HK1218760A1
HK1218760A1 HK16106674.2A HK16106674A HK1218760A1 HK 1218760 A1 HK1218760 A1 HK 1218760A1 HK 16106674 A HK16106674 A HK 16106674A HK 1218760 A1 HK1218760 A1 HK 1218760A1
Authority
HK
Hong Kong
Prior art keywords
composition
protein
fxa variant
light chain
core
Prior art date
Application number
HK16106674.2A
Other languages
English (en)
Chinese (zh)
Inventor
．揚科斯基
M．A．扬科斯基
．約翰遜
K．A．约翰逊
．皮阿森扎
W．C．皮阿森扎
．羅斯
J．C．罗斯
．沙馬施金
M．沙马施金
．夏泊
P．J．夏泊
．斯威澤
M．B．斯威泽
．韋斯頓
S．B．韦斯顿
Original Assignee
辉瑞大药厂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 辉瑞大药厂 filed Critical 辉瑞大药厂
Publication of HK1218760A1 publication Critical patent/HK1218760A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
HK16106674.2A 2013-09-24 2014-09-16 包含重组人凝血因子xa蛋白的异质性群体的组合物 HK1218760A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24
US61/881,834 2013-09-24
PCT/IB2014/064564 WO2015044836A1 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Publications (1)

Publication Number Publication Date
HK1218760A1 true HK1218760A1 (zh) 2017-03-10

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106674.2A HK1218760A1 (zh) 2013-09-24 2014-09-16 包含重组人凝血因子xa蛋白的异质性群体的组合物

Country Status (19)

Country Link
US (3) US9757434B2 (https=)
EP (1) EP3049434A1 (https=)
JP (1) JP6429885B2 (https=)
KR (1) KR101988705B1 (https=)
CN (2) CN112195169A (https=)
AR (1) AR097732A1 (https=)
AU (1) AU2014326257B2 (https=)
BR (1) BR112016005899A8 (https=)
CA (1) CA2924981C (https=)
HK (1) HK1218760A1 (https=)
IL (2) IL244258A0 (https=)
MX (1) MX373466B (https=)
MY (1) MY173548A (https=)
PE (1) PE20160877A1 (https=)
RU (1) RU2648144C2 (https=)
SA (1) SA516370751B1 (https=)
SG (1) SG11201601221XA (https=)
TW (1) TWI631134B (https=)
WO (1) WO2015044836A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
PT3472314T (pt) * 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
MX2011004907A (es) * 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
TW201217527A (en) * 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP3063170A4 (en) 2013-11-01 2017-06-28 The Children's Hospital of Philadelphia Compositions and methods for increasing the half-life of factor xa
BR112016014617A2 (pt) 2014-01-24 2017-09-19 Pfizer Variante do fator xa (fxa) e usos da referida variante

Also Published As

Publication number Publication date
RU2016108608A (ru) 2017-10-26
JP6429885B2 (ja) 2018-11-28
WO2015044836A1 (en) 2015-04-02
KR20160044034A (ko) 2016-04-22
US20210106658A1 (en) 2021-04-15
BR112016005899A8 (pt) 2018-02-06
AU2014326257A1 (en) 2016-03-10
TWI631134B (zh) 2018-08-01
MY173548A (en) 2020-02-04
SA516370751B1 (ar) 2018-04-05
US20150182604A1 (en) 2015-07-02
IL279396A (en) 2021-01-31
MX373466B (es) 2020-05-25
TW201524996A (zh) 2015-07-01
PE20160877A1 (es) 2016-09-11
US10660946B2 (en) 2020-05-26
US9757434B2 (en) 2017-09-12
CN105579468A (zh) 2016-05-11
EP3049434A1 (en) 2016-08-03
US20170333535A1 (en) 2017-11-23
MX2016003871A (es) 2016-08-04
SG11201601221XA (en) 2016-04-28
CN112195169A (zh) 2021-01-08
BR112016005899A2 (pt) 2017-09-26
JP2016535071A (ja) 2016-11-10
RU2648144C2 (ru) 2018-03-22
AU2014326257B2 (en) 2017-08-10
CA2924981A1 (en) 2015-04-02
KR101988705B1 (ko) 2019-06-12
IL244258A0 (en) 2016-04-21
AR097732A1 (es) 2016-04-13
CA2924981C (en) 2020-03-31

Similar Documents

Publication Publication Date Title
US20210106658A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP2108045B1 (en) Improved fix-mutant proteins for hemophilia b treatment
EP1863920B1 (en) Method for improved isolation of recombinantly produced proteins
EP2108046B1 (en) Fviii-independent fix-mutant proteins for hemophilia a treatment
CA2683423C (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
US9896677B2 (en) Purification of blood coagulation factors
CN103814137A (zh) 处理凝血因子的方法
AU2014202989B2 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
HK40007078A (en) Method for isolation of recombinantly produced proteins
WO2017025566A1 (en) Improved recombinant factor vii
HK1178048A (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
AU2016238889A1 (en) Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same